Kajsa Larsson, CMO, on the upcoming Phase III studies of linaprazan glurate
Highlights from the 2024 Annual Report: Interview with Kajsa Larsson. The study will involve around 500 patients from eight countries in Europe and North America, with up to 100 hospitals and clinics.
Read more